Fosamax Cancer Risk Signal Review: What the Evidence Actually Shows

Why Cancer Risk Signals Emerge With Alendronate

Alendronate is a nitrogen-containing bisphosphonate that adsorbs to hydroxyapatite on bone surfaces and inhibits farnesyl pyrophosphate synthase in osteoclasts. That same mevalonate-pathway inhibition affects prenylation of signaling proteins such as Ras and Rho in epithelial and tumor cells, which is why researchers began examining cancer incidence in bisphosphonate-exposed populations in the late 1990s.

Mechanism: Mevalonate Pathway and Tumor Biology

Farnesyl pyrophosphate synthase inhibition depletes downstream isoprenoids needed for post-translational modification of GTPases. In vitro, this triggers apoptosis and reduces proliferation in breast, colon, and prostate cancer cell lines. Studies published in Cancer Research confirm that nitrogen-containing bisphosphonates dose-dependently induce apoptosis in MCF-7 breast cancer cells, which supplied the biological rationale for subsequent epidemiological work.

How Regulatory Signals Are Generated

Pharmacovigilance signals arise from spontaneous adverse event reports submitted to the FDA MedWatch system and from large healthcare database studies. The FDA's Adverse Event Reporting System (FAERS) forms the first layer of signal detection, followed by disproportionality analyses, and then formal epidemiological studies. For alendronate, the esophageal cancer signal followed exactly this sequence between 2008 and 2012.

A critical interpretive issue is that osteoporosis itself is linked to lower body weight and lower estrogen exposure, both of which independently alter cancer risk. Confounding by indication therefore complicates nearly every observational study in this space.

Esophageal Cancer: The Clearest Regulatory Signal

The FDA issued a drug safety communication in 2008 and updated its guidance in 2012 after spontaneous reports and a UK-based cohort study linked oral bisphosphonate use to esophageal cancer.

The Cardwell 2010 BMJ Study

Cardwell et al. Analyzed 79 esophageal and 1,114 other cancers in a UK General Practice Research Database cohort of 41,826 bisphosphonate users matched to 41,826 non-users. Their analysis in BMJ 2010 found an adjusted odds ratio of 1.30 (95% CI 1.02 to 1.66) for esophageal cancer with 5 or more prescriptions, corresponding to roughly 1 additional case per 1,000 treated patients over 5 years.

The Green 2010 BMJ Rebuttal

Published in the same issue, Green et al. Used the same UK database and found no significantly elevated risk (relative risk 1.07, 95% CI 0.77 to 1.49). This counter-analysis illustrated how differently studies using identical data sources can be constructed and how sensitive the signal is to case-definition criteria, latency windows, and comparator group selection.

FDA Position After 2012

The FDA concluded that a causal relationship between oral bisphosphonates and esophageal cancer could not be ruled out, though absolute risk remained low. The agency mandated updated prescribing information requiring clinicians to advise patients to stop the drug and seek evaluation for any new dysphagia, odynophagia, or retrosternal pain. The full 2012 FDA update is accessible here.

The prescribing information now states: "Instruct patients to stop taking alendronate and seek medical attention if they develop symptoms of esophageal disease (such as difficulty or pain upon swallowing, retrosternal pain, or new or worsening heartburn)."

Biologically, the esophageal signal is plausible. Tablets that lodge in the esophagus cause direct mucosal injury, and repeated inflammation is an established carcinogenesis pathway. Adherence to the dosing protocol, specifically 6 to 8 oz of plain water followed by 30 minutes upright, substantially reduces this risk.

Breast Cancer: A Possible Protective Signal

Observational Evidence Favoring Reduced Risk

Multiple large observational studies report a 30 to 40 percent lower breast cancer incidence in bisphosphonate users. The Women's Health Initiative study (N=154,768) found that bisphosphonate use was associated with a 32% lower invasive breast cancer risk (hazard ratio 0.68, 95% CI 0.52 to 0.88) after adjustment for hormone therapy and mammography frequency.

The Israeli Study and Zoledronic Acid Data

A large Israeli case-control study (N=4,039 cases) found that any bisphosphonate use for more than one year was associated with a 39% reduction in breast cancer risk (odds ratio 0.61, 95% CI 0.43 to 0.86). The AZURE trial, although primarily a bone metastasis prevention study, also generated data suggesting zoledronic acid reduced new primary breast cancers in postmenopausal women, lending biologic consistency to the alendronate findings via shared mechanism.

Why Causal Inference Remains Difficult

Postmenopausal women who receive alendronate are screened more frequently and have different hormonal profiles than women who do not. Healthy-user bias, detection bias, and confounding by estrogen exposure all threaten these estimates. No randomized controlled trial with breast cancer incidence as a primary endpoint has been completed for alendronate specifically. A 2022 Cochrane systematic review of bisphosphonate breast cancer prevention trials noted insufficient evidence to recommend bisphosphonates outside of bone-health indications.

Clinicians should not prescribe alendronate for breast cancer prevention. The observational signal is hypothesis-generating, not practice-changing.

Colorectal Cancer: Inconsistent but Mostly Reassuring Data

Primary Case-Control and Cohort Findings

Several population-based analyses suggest bisphosphonate users have a lower risk of colorectal cancer. A nested case-control study in JAMA Internal Medicine (2012) among 933 colorectal cancer cases found that bisphosphonate use for more than 2 years was associated with an odds ratio of 0.76 (95% CI 0.60 to 0.97) compared to non-users.

The mechanism proposed involves bisphosphonate-induced apoptosis in colonic epithelial cells, inhibition of Ras-mediated proliferation, and possible anti-inflammatory effects. Preclinical data from the NCI support mevalonate-pathway interference as an antiproliferative mechanism in colon cancer cell lines.

Studies Showing Null Results

Not all databases replicate this finding. A Danish nationwide cohort study (N=36,792 bisphosphonate users) found no statistically significant reduction in colorectal cancer risk (relative risk 0.93, 95% CI 0.79 to 1.09). The heterogeneity across studies likely reflects differences in follow-up duration, bisphosphonate type, dose, and ascertainment of cancer outcomes.

No regulatory agency has modified colorectal cancer screening recommendations based on bisphosphonate use. Standard colonoscopy intervals per USPSTF guidelines apply regardless of alendronate exposure.

Osteosarcoma: A Theoretical Risk Grounded in Rodent Data

Animal Data That Started the Concern

The osteosarcoma concern originated from 2-year rat carcinogenicity studies conducted during alendronate's development. At doses 3.75 to 6.25 mg/kg per day, which translate to exposures far exceeding the 10 mg/day human therapeutic dose, male rats developed dose-dependent increases in osteosarcoma incidence. The FDA label discloses these findings while noting they occurred only at supratherapeutic exposures.

Human Epidemiological Data

Human data do not support a causal link. A Swedish registry-based study (N=5,592 osteosarcoma cases) found no increased incidence of osteosarcoma in bisphosphonate users after adjustment for age and indication. The background incidence of osteosarcoma in adults is approximately 1 to 3 per million per year, making any drug-attributable signal statistically challenging to detect even in large registries.

The FDA product labeling for alendronate includes a precautionary statement about osteosarcoma based on the rodent data, but this has not translated into a clinical warning or a requirement for additional monitoring in human patients.

Distinguishing Alendronate From Teriparatide: The Osteosarcoma Contrast

Teriparatide (Forteo), the recombinant PTH(1-34) analog, carries a boxed warning for osteosarcoma based on similar rat carcinogenicity data combined with a mechanism (osteoblast stimulation) more directly linked to osteosarcoma biology. Alendronate suppresses osteoclast activity rather than driving osteoblast proliferation. This mechanistic difference is why the two drugs carry different warning levels for osteosarcoma despite both generating rodent signals.

FDA safety labeling comparisons for teriparatide and alendronate illustrate this distinction clearly. Alendronate lacks the boxed warning that teriparatide carries.

The FIT Trial: What the Primary Efficacy Data Actually Show About Cancer

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) was a 3-year randomized, double-blind, placebo-controlled trial of alendronate 5 mg/day (later increased to 10 mg/day) in postmenopausal women with low femoral neck bone density. FIT demonstrated a 47% relative risk reduction in morphometric vertebral fractures (relative risk 0.53, 95% CI 0.41 to 0.68) and a 51% reduction in clinical vertebral fractures. The trial was not powered to detect cancer endpoints, and cancer incidence was not a prespecified secondary outcome.

The table below summarizes the cancer signal status across tissue types for clinicians making prescribing decisions.

| Cancer Site | Signal Direction | Highest Quality Evidence | Regulatory Action | |---|---|---|---| | Esophageal | Possible increase | Cardwell 2010 BMJ cohort | FDA safety communication 2008, 2012 | | Breast | Possible decrease | WHI cohort (N=154,768) | None; no indication change | | Colorectal | Possible decrease | JAMA Intern Med 2012 nested case-control | None | | Osteosarcoma | No human signal | Swedish registry N=5,592 | Precautionary label note only | | Bone (all) | No signal | FIT (N=2,027), 3-year RCT | None |

Long-Term Use and Drug Holiday Considerations

The American Society for Bone and Mineral Research (ASBMR) Task Force recommends reassessment of bisphosphonate therapy after 3 to 5 years of oral bisphosphonate use in lower-risk patients. This recommendation is driven primarily by atypical femoral fracture and osteonecrosis of the jaw risk, not by cancer risk. Cancer monitoring during a drug holiday is not part of current ASBMR or Endocrine Society guidelines.

Who Should Not Take a Drug Holiday

Patients with a T-score below negative 2.5 at the hip after 5 years of treatment, a prior vertebral or hip fracture, or ongoing high-dose glucocorticoid exposure should continue therapy without a planned holiday according to the 2022 AACE/ACE clinical practice guidelines for postmenopausal osteoporosis. For these patients, the fracture risk of stopping treatment exceeds any theoretical cancer signal.

Practical Monitoring During Therapy

No cancer-specific laboratory or imaging monitoring is required during alendronate therapy beyond standard osteoporosis surveillance. Bone mineral density reassessment every 1 to 2 years during active therapy and every 2 to 3 years during a drug holiday is standard per NOF guidelines. Any new dysphagia warrants upper endoscopy regardless of alendronate use, but alendronate should be stopped while esophageal evaluation is pending.

Esophageal Cancer Risk Minimization: Practical Protocol

Three adherence points reliably reduce esophageal injury risk. First, take the tablet with 6 to 8 oz (180 to 240 mL) of plain water only. Second, remain fully upright (sitting or standing) for at least 30 minutes after ingestion. Third, take the dose on an empty stomach at least 30 minutes before the first food, beverage, or other medication of the day. Patients who cannot reliably maintain upright posture for 30 minutes should use intravenous zoledronic acid 5 mg annually instead.

Weekly alendronate 70 mg (the most commonly prescribed formulation) carries the same esophageal precautions as the daily 10 mg formulation. The FDA-approved labeling specifies these instructions identically for both schedules.

Interpreting Absolute Versus Relative Risk

The Cardwell BMJ analysis reported a relative odds ratio of 1.30 for esophageal cancer with 5 or more bisphosphonate prescriptions. The absolute risk increase was approximately 1 case per 1,000 users over 5 years. Background esophageal cancer incidence in women over 60 is roughly 3 to 4 per 100,000 per year; adding 1 per 1,000 over 5 years raises that to approximately 5 to 6 per 100,000 per year. Compare this to the absolute fracture reduction from alendronate: FIT showed approximately 8 fewer clinical vertebral fractures per 100 treated women over 3 years.

For most patients meeting WHO FRAX thresholds for treatment, the fracture reduction benefit exceeds the esophageal cancer risk by a margin of roughly 80-fold on an events-prevented versus events-caused basis.